Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.

Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.

Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?